scholarly journals Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial

2018 ◽  
Vol 120 (2) ◽  
pp. 164-175 ◽  
Author(s):  
Christina N. Katsagoni ◽  
George V. Papatheodoridis ◽  
Panagiota Ioannidou ◽  
Melanie Deutsch ◽  
Alexandra Alexopoulou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Mediterranean Diet ◽  
Fatty Liver Disease ◽  
Liver Stiffness ◽  
Alcoholic Fatty Liver ◽  
Randomised Controlled ◽  
Alcoholic Fatty Liver Disease

AbstractLifestyle interventions remain the cornerstone therapy for non-alcoholic fatty liver disease (NAFLD). This randomised controlled single-blind clinical trial investigated the effect of Mediterranean diet (MD) or Mediterranean lifestyle, along with weight loss, in NAFLD patients. In all, sixty-three overweight/obese patients (50 (sd11) years, BMI=31·8 (sd4·5) kg/m2, 68 % men) with ultrasonography-proven NAFLD (and elevated alanine aminotransferase (ALT) and/or γ-glutamyl transpeptidase (GGT) levels) were randomised to the following groups: (A) control group (CG), (B) Mediterranean diet group (MDG) or (C) Mediterranean lifestyle group (MLG). Participants of MDG and MLG attended seven 60-min group sessions for 6 months, aiming at weight loss and increasing adherence to MD. In the MLG, additional guidance for increasing physical activity and improving sleep habits were given. Patients in CG received only written information for a healthy lifestyle. At the end of 6 months, 88·8 % of participants completed the study. On the basis of intention-to-treat analysis, both MDG and MLG showed greater weight reduction and higher adherence to MD compared with the CG (allP<0·05) at the end of intervention. In addition, MLG increased vigorous exercise compared with the other two study groups (P<0·001) and mid-day rest/naps compared with CG (P=0·04). MLG showed significant improvements in ALT levels (i.e. ALT<40 U/l (P=0·03) and 50 % reduction of ALT levels (P=0·009)) and liver stiffness (P=0·004) compared with CG after adjusting for % weight loss and baseline values. MDG improved only liver stiffness compared with CG (P<0·001) after adjusting for the aforementioned variables. Small changes towards the Mediterranean lifestyle, along with weight loss, can be a treatment option for patients with NAFLD.

The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial

2015 ◽  
Vol 36 (4) ◽  
pp. 563-571 ◽  
Author(s):  
Mohsen Razavi Zade ◽  
Mohammad Hosein Telkabadi ◽  
Fereshteh Bahmani ◽  
Behnaz Salehi ◽  
Shima Farshbaf ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Randomized Clinical Trial ◽  
Fatty Liver Disease ◽  
Metabolic Status ◽  
Alcoholic Fatty Liver ◽  
Dash Diet ◽  
Alcoholic Fatty Liver Disease

scholarly journals The Impact of Combined Cranberry Supplementation and Weight Loss Diet on Inflammatory, Antioxidant and Apoptosis Biomarkers in Patients with Non-Alcoholic Fatty Liver Disease

2021 ◽  
Author(s):  
Majid Mohammadshahi ◽  
Razie Hormoznejad ◽  
Fakher Rahim ◽  
Bijan Helli ◽  
Pezhman Alavinejad ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Levels ◽  
Alcoholic Fatty Liver ◽  
Weight Loss Diet ◽  
Tnf Α ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver diseases. The aim of this study was to evaluate the effect of combined weight loss diet and cranberry supplementation on inflammatory, antioxidant and apoptosis biomarkers in patients with NAFLD. Methods In this randomized, double-blinded, controlled clinical trial, 41 NAFLD patients were supplemented with either a 288-mg cranberry tablet or a placebo tablet for 12 weeks. Both groups followed a diet of 500–1000 calories less than the estimated energy requirements. Serum levels of Total antioxidant capacity (TAC), Malondialdehyde (MDA), Cytokeratin 18-M30 (CK-18 M30), Chemokine C-C motif ligand 2 (CCL2) and Tumour necrosis factor alpha (TNF-α) were measured at both baseline and the end of the study. Results Significant improvements in TAC were observed in the cranberry group and between the two groups (p = 0.006 and p = 0.011 respectively), but the changes in the placebo group were not significant (p = 0.325). There were no statistically significant differences in the serum levels of MDA, CK-18 M30, CCL2 and TNF-α between the cranberry and the placebo groups (p > 0.05). Conclusions It seems that daily consumption of cranberry supplement would be beneficial in increasing serum levels of TAC. Further studies are needed to investigate the effects of anti-inflammatory and antioxidant properties of cranberry on NAFLD. Trial registration : Iranian Registry of Clinical Trial. http://www.irct.ir: IRCT20150124020765N2, January 2019.

scholarly journals Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e045922
Author(s):  
Laura Haigh ◽  
Stuart McPherson ◽  
John C Mathers ◽  
Quentin M Anstee
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Controlled Trial ◽  
Phase 1 ◽  
Feasibility Trial ◽  
Alcoholic Fatty Liver ◽  
Intervention Protocol ◽  
Randomised Controlled ◽  
Alcoholic Fatty Liver Disease

IntroductionLifestyle interventions targeting weight loss and improved dietary patterns are the recommended treatment for non-alcoholic fatty liver disease (NAFLD). However, the effectiveness of current established diet therapies is suboptimal. The patatin‐like phospholipase domain containing 3 (PNPLA3) gene modifies disease outcome and hepatic lipid handling, but the role of PNPLA3 variants in modulating responsiveness to different diet therapies is unknown.Methods and analysisThis project aims to assess the feasibility of conducting a genotype-driven randomised controlled trial (RCT) investigating the differential response to a Mediterranean diet (MD) intervention of NAFLD patients according to genotype for the rs738409 (I148M) variant of PNPLA3. A single-centre randomised controlled feasibility trial will be undertaken. We will recruit 60 adults with NAFLD from a tertiary hepatology centre in England. In a cross-over design, participants will undertake Diet 1 (MD) and Diet 2 (control) for 4 weeks, in random order (1:1 allocation), separated by a 4 weeks washout period. Participants will complete one-to-one diet and lifestyle consultations at baseline, end of diet phase 1, end of washout and end of diet phase 2. Participants will be advised to maintain baseline levels of physical activity and body weight. The primary outcome is the acceptability and feasibility of the intervention protocol. Secondary outcomes include exploratory assessment of liver fibrosis biomarkers and lipid biomarkers.Ethics and disseminationEthical approval was granted by East of Scotland Research Ethics Service REC 1 (19/ES/0112). Results will be disseminated through peer-reviewed journals and presented at local, national and international meetings and conferences. The findings of this trial will lay the foundation for a future definitive RCT by informing trial design and optimising the intervention diets, instruments and procedures.Trial registration numberISRCTN93410321.

Sign in / Sign up

Export Citation Format

Share Document